AU2011221386A1 - Stable injectable diclofenac compositions - Google Patents

Abstract

Abstract This invention relates to stable parenteral aqueous solutions comprising either (a) diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or (b) an inclusion complex of diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or a mixture of (a) and (b), which are suitable for intramuscular and intravenous administration. The solutions contain diclofenac or diclofenac salt, cyclodextrin, and an antioxidant selected from monothioglycerol, or a combination of ethylene diamine tetra-acetic and N-acetyl cysteine.

Description

AUSTRALIA Patents Act COMPLETE SPECIFICATION (ORIGINAL) Class Int. Class Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority Related Art: Name of Applicant: Shimoda Biotech (Pty) Ltd Actual Inventor(s): Lawrence John Penkler Address for Service and Correspondence: PHILLIPS ORMONDE FITZPATRICK Patent and Trade Mark Attorneys 367 Collins Street Melbourne 3000 AUSTRALIA Invention Title: STABLE INJECTABLE DICLOFENAC COMPOSITIONS Our Ref: 924039 POF Code: 228799/478806 The following statement is a full description of this invention, including the best method of performing it known to applicant(s): -1 - - la STABLE INJECTABLE DICLOFENAC COMPOSITIONS The present application is a divisional application from Australian patent application number 2004317520, the entire disclosure of which is incorporated herein by reference. 5 BACKGROUND TO THE INVENTION Diclofenac is a leading non-steroidal anti-inflammatory drug (NSAID). The drug has been in clinical use for over two decades as a NSAID with analgesic, anti-inflammatory and anti 10 pyretic activity. Historically, diclofenac has been associated mainly with chronic management of inflammatory and degenerative forms of rheumatism as well as treatment of painful musculoskeletal conditions, acute attacks of gout, painful post-operative and post-traumatic inflammation and pain following dental surgery. For these conditions the drug has been available in delayed release enteric coated tablets, sustained release tablets, suppositories 15 and ampoules for strict intramuscular injection. More recently, diclofenac has become available in rapid acting oral preparations for short term treatment of acute conditions. Since 1995, diclofenac sodium is available in the UK and Scandinavia as an intravenous infusion indicated for moderate to severe post-operative pain, or for the prophylaxis of post-operative pain. 20 Conventionally formulated diclofenac sodium injections are limited to intramuscular administration. This limitation has arisen, not as a consequence of the intravenous safety profile, but principally due to the physico-chemical properties of the drug, summarized as follows: 25 - Poor aqueous solubility of the sodium salt - Diclofenac has a particularly high tendency to crystallize from aqueous and organic solutions. Physically stable solutions containing at least 25 mg/ml of diclofenac sodium necessitates the use of potent solubilizing cosolvents, such as macrogols and benzyl alcohol. These 30 cosolvents have an unfavourable intravenous safety WO 2005/092387 PCT/IB2004/003918 -2 profile and are associated with venous sequelae, high haemolytic and sensitising potential (see Reed, K.W. et al, J. Par. Sci. Technol. 39(2) (1985) 64-68). " Susceptibility to oxidation - Diclofenac's tendency to oxidize in solution necessitates formulation with antioxidants, for example sulphite salts. In the commercial European intramuscular product, antioxidants such as sodium metabisulphite or sodium disulphite are usually used. Sulphite salts have been implicated in serious hypersensitivity reactions causing, for example, broncho-constriction (see Gunnison, A.F. et al, CRC Critical Reviews In Toxicology 17(3)(1987) 185-214). " pH and Osmolality - The high pH of the marketed product (ca. 8.5) required to render diclofenac sodium soluble and the hyperosmolar nature of the formulation contribute to the discomfort which is frequently experienced at the site of the injection when administered intramuscularly. " Injection Volume - Owing to poor solubility, the commercial product is formulated as 25mg diclofenac sodium per millilitre. The recommended dosage Is 75mg and therefore the product Is given as a 3 millilitre intramuscular Injection. This is above the recommended volume of 2 millllitres for intramuscular Injection accepted by the United States Food and Drug Administration. US 5,679,660 to Farmarc Nederland BV teaches a method of preparing an injectable pharmaceutical or veterinary composition which comprises either diclofenac or a salt thereof and 2-hydroxypropyl beta-cyclodextrin with a preferred concentration of diclofenac of 25mg per millilitre. This reference discloses a method whereby the aqueous solubility of diclofenac was Increased with the aid of a cyclodextrin to the extent that It could be formulated Into a parenteral formulation containing 75mg diclofenac per 3ml. The formulatory volume of 3ml is not problematic with regard to the WO 2005/092387 PCT/IB2004/003918 -3 Intravenous dosage route, as the drug will possibly be given by infusion, but as far as the intramuscular dosage form is concerned, a volume of 3ml will not meet with FDA approval. It has been found that solutions of diclofenac sodium in 2-hydroxypropyl beta-cyclodextrin prepared according to US 5,679,660 with a dlclofenac sodium concentration of 25 mg per millilitre are stable for up to 12 months at room temperature and at least 24 months under refrigerated conditions. After 12 months at room temperature and 4 months at elevated temperature (e.g. 40 *C), appearance of visible insoluble particulate matter occurs which progresses with time. In order to satisfy a 24 month pharmaceutical shelf-life, the injectable product should be stored under refrigerated conditions. A refrigerated parenteral product however has the disadvantage of discomfort upon injection due to the low temperature of the Injected product coupled with the increased cost of product storage. It is an object of this Invention to provide a parenteral dosage form of diclofenac which addresses the aforementioned limitations and which may be used for both intramuscular and intravenous administration. SUMMARY OF INVENTION According to the Invention there Is provided a stable parenteral aqueous solution comprising either (a) diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or (b) an Inclusion complex of diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or a mixture of (a) and (b), which Is preferably suitable for intramuscular and intravenous administration, the solution containing: * diclofenac or diclofenac salt, preferably diclofenac sodium; * cyclodextrin, typically 2-hydroxypropyl beta-cyclodextrin; and WO 2005/092387 PCTJ[B2004/003918 -4 . an antioxidant selected from monothloglycerol, or a combination of ethylene diamine tetra-acetic acid and N-acetyl-cysteine. The molar ratio of diclofenac to 2-hydroxypropyl beta-cyclodextrin Is preferably 1:1.5 to 1:2.5, most preferably 1:2. Typically, the solution comprises 20mg to 45mg, preferably more than 25mg, most preferably 37.5mg, diclofenac or diclofenac salt per millilitre solution. Where the antioxidant is monothioglycerol, the monothioglycerol may comprise 0.1 to 10 mg, preferably 0.1 to 5 mg, most preferably 5 mg, per millilitre solution. Where the antioxIdant is a combination of ethylene diamine tetra-acetic acid and N-acetyl-cysteine, the ethylene diamine tetra-acetic acid may comprise 0.05 to 1 mg, preferably 0.5 mg, per millilitre solution and the N acetyl-cystelne may comprise 0.1 to 2 mg, preferably 1 mg, per millilitre solution. Advantageously, the solution is in the form of a unit dose that does not exceed 2 millilitres. DETAILED DESCRIPTION OF THE INVENTION The inventor has found a way to prepare an aqueous solution comprising either (a) diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or (b) an inclusion complex of diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or a mixture of (a) and (b), which is not only capable of having a concentration of dlclofenac or diclofenac salt of more than 25 mg per millilitre of solution, but is also stable and does not need to be refrigerated when packed in clear glass pre-fillable syringes. By 'stable" Is meant that the solution can be stored for at least 12 WO 2005/092387 PCT/IB2004/003918 -5 months at room temperature and at least 6 months at elevated temperature (40 0 C) without the appearance of particulate matter which Is visible to the eye. The use of an antioxidant In the form of monothloglycerol (MTG) or a combination of ethylene diamine tetra-acetic acid (EDTA) and N-acetyl cystelne (NAC) has been found to not only increase the diclofenac solubility to the extent that it is possible to dissolve 75mg of diclofenac-cyclodextrin into a final volume of 2ml (which means that the solubility of diclofenac (which is a very poorly water soluble drug) has been Increased to such an extent that it could be formulated in a final volume 33% less than that proposed In US 5,679,660), but also effectively stabilises the solution preventing the formation of particulate matter at elevated temperature in pre-fillable syringes, ampoules and vials. The solution may be formulated in unit dose form, each unit dose containing from 10 mg to 150 mg diclofenac or diclofenac salt inclusive, more preferably from 25mg to 75mg inclusive, most preferably 75 mg, In a volume not exceeding 2 millilitres. The 2-hydroxypropyl beta-cyclodextrin (HPBCD) is selected from derivatives with a degree of substitution of between 2.5 and 10 hydroxypropyl substitutents per beta-cyclodextrin molecule, more preferably between 3.5 and 8 hydroxypropyl substitutents per beta cyclodextrin molecule. The molar ratio of diclofenac to 2-hydroxypropyl beta-cyclodextrin Is 1:1 to 1:10, more preferably 1:1.5 to 1:2.5, most preferably 1:2. The injectable stabilised solution of the invention may be prepared by methods known In the art (e.g. US 5,679,660, the content of which is Incorporated herein by reference). The stabillsed injectable solution of the Invention may be packed Into suitable containers known In the art (for example glass ampoules, vials, WO 2005/092387 PCT/IB2004/003918 -6 cartridges, pre-filled syringes and the like). The glass should preferably be clear glass. The stabilised injectable solution of the invention may be intravenously administered by admixture with non dextrose infusion fluids. The stabilized injectable solution of the invention is suitable for intravenous and intramuscular use, saving money with regard to manufacturing cost and provides the patient with less discomfort due to a smaller intramuscular injection volume. The stabilized injectable solution of the invention need not be stored under refrigerated conditions to provide a shelf life of at least 24 months, saving refrigeration costs during transport and storage, and alleviating patient discomfort during administration. The antioxidants of the Invention show advantages over a control solution containing no antioxidant and solutions containing other antioxidants, namely NAC or EDTA by themselves, sodium formaldehyde sulphoxilate (SFS) by Itself and a combination of SFS and EDTA. Tables I and 2 below show stability evaluations of 75mg per 2ml diclofenac sodium formulations prepared according to the process disclosed in US 5,679,660 stored at 40 0 C for 3 and 6 months respectively. It is evident from Tables 1 and 2 that whereas the NAC EDTA combination and monothloglycerol formulations according to the invention are stable after 6 months at 40 0 C, formulations containing NAC or EDTA by themselves, SFS by itself and a combination of SFS and EDTA are not stable.

WO 2005/092387 PCT/IB2004/003918 -7 Table 1 Stability Evaluation Of 75mq/2mi Diclofenac Sodium Antioxident Batches at 40 0 C For 3 Months Antioxidant Chemical pH Appearance/Particulate Comments stability trend matter at 40CC Control (No Acceptable Upward Discolouration; physical Not stable additives) level of Instability (+++) (continued to 6 known months as degradant control) EDTA 0.05% Acceptable Slightly Discolouratlon; physical Product not level of upward Instability (+++) stabilised known sufficiently-trial degradant discontinued NAC 0.1% Acceptable Slightly Stable Complies, trial level of upward continued known degradant NAC 0.1% + Acceptable Stable Stable Complies, trial EDTA 0.05% level of continued known degradant I Monothioglycerol Acceptable Slightly Stable Complies, trial 0.1% level of upward continued known degradant Monothloglycerol Acceptable Slightly Stable Complies, trial 0.5% level of upward continued known degradant Thioglycerol 0.1% Acceptable Sllghtly Stable Complies, trial + EDTA 0.05% level of upward continued known degradant SFS 0.005% New Upward Physically unstable (+++) Not stable-tral degradant discontinued which exceeds 0.1% m/m SFS 0.1% New Slightly DIscolouration; physically Not stable-trial degradant upward unstable, but more stable discontinued which than 0.005% solution (++) exceeds 0.1% m/m SFS 0.005% + Acceptable Slightly Physically unstable (++) Not stable-trial EDTA 0.05% level of upward discontinued known degradant I I Key (+) = Very few colloIdal particulates, fibres or filling artefacts (++) = Evidence of physical instability under light (+++.) = Physical instability readily observable with the naked eye WO 2005/092387 PCT/IB2004/003918 -8 Table 2 Stability Evaluation of 75mq/2ml Diclofenac Sodium AntiOxidant Batches at 40 0 C after 6 Months Antioxidant Chemical pH Appearance/Particulate Comments stability trend matter at 40*C Control (No Acceptable Upward Discolouration; physical Not stable additives) level of Instability (+++) (Control) known degradant NAC 0.1% Acceptable Slightly Discolouration; physical Not stable level of upward Instability (+++) known degradant NAC 0.1% + Acceptable Slightly Clear, straw colour - Formulation EDTA 0.05% level of upward some particulate matter possible known degradant Monothioglycerol Acceptable Slightly Clear, straw colour - Formulation 0.1% level of upward some particulate matter possible known (4) degradant Monothioglycerol Acceptable Slightly Clear, straw colour - Formulation 0.5% level of upward some particulate matter possible known (+) degradant I Monothloglycerol Acceptable Slightly Clear, straw colour - Formulation 0.1% + EDTA level of upward some particulate matter possible 0.05% known (+) degradant _ Key: (+) = Very few colloidal particulates, fibres or filling artefacts (++) = Evidence of physical instability under light (++) - Physical Instability readily observable with the naked eye The Invention will now be described in more detail with reference to the following non-limiting examples. EXAMPLE 1 The unit composition of a first preferred formulation of the invention is provided in Table 3 below: WO 2005/092387 PCT/IB2004/003918 -9 Table 3 'Ingredient Quantityl2mi Diclofenac Sodium 75 mg Hydroxypropyl-&1-cyclodextrin 666 mg N-acetyl-L-cysteine 2 mg Disodium edetate (EDTA) 1 mg Water for Injection to 2 ml Final pH 6.5-8.5 EXAMPLE 2 The unit composition of a second preferred formulation of the invention is provided In Table 4 below: Table 4 Ingredient Quantity/2ml Diclofenac Sodium 75 mg 2-Hydroxypropyl-&-cyclodextrin 666 mg Monothloglycerol 10 mg Water for Injection to 2 ml Final pH 6.5 - 8.5 EXAMPLE 3 Laboratory-scale formulations given in Examples 1 and 2 of the present invention were manufactured according to Example 4 of US 5,679,660 and filled into clear glass prefillable syringes and placed on a stability program. Table 5 below summarizes the results obtained: WO 2005/092387 PCT/1B2004/003918 -10 Table 5 STABILITY DATA FOR STABILIZED 75mgf2ml DICLOFENAC SODIUM-HPB SOLUTIONS Stabilised by: 0.5% m/v monothioglycerol Stabillsed by 0.05% m/v EDTA & 0.1% m/v NAC T= 6 months T=6 months 25'C 40*C 25 0 C 40C Appearance Clear Clear, straw Appearance Clear, Clear, straw colourless coloured colourless coloured solution solution solution solution PH 7.44 8.12 PH 7.17 8.16 Particulate Free from Free from Particulate Free from Free from Matter visible visible Matter visible visible particulate particulate particulate particulate matter matter matter matter Assay (HPLC) - 100% -99% Assay (HPLC) ~ 100% -99% (% of T=O) (% of T=O) Indolinone <0.1% m/m 0.57% Indolinone <0.1% 0.53% m/rn Other None None Other None None degradants detected detected degradants detected detected Control solutions at 400C for 6 months showed heavy precipitation of an insoluble red-coloured material. After 24 months at 25*C the solution containing monothloglycerol remained clear and slightly coloured, free from visible particulate matter. The associated solution containing N-acteyl-cysteine/EDTA was clear but more darkly colored than the monothioglycerol solution. EXAMPLE 4 To produce 250 75mg/2ml diclofenac sodium units for IM or IV Injection, 500ml water for Injection (WFI) is purged with nitrogen gas to reduce the oxygen content to less than 0.5 mg/. The water was heated to 50 0 C. Processing continues under a nitrogen gas blanket. 166.675g of HPBCD (DS 4.69) Is added to 60% of the WFI batch volume and Is mixed until dissolved. The solution is then allowed to cool to room temperature. The solution is pre-filtered with a 0.45pg filter, followed by the addition of 2.5 g MTG. The solution is stirred until all the MTG is dissolved. The pH is then adjusted to 4.5. 18.75 g diclofenac sodium Is added to the solution and stirred until dissolved and made up to 100% volume with WFI and the pH is adjusted to 7.4, should it be required. The resultant 75mg/2ml diclofenac WO 2005/092387 PCT/IB2004/003918 -11 sodium solution Is sterilized by filtration with 0.22pm filters and filled into pre-sterilized ampoules/vials under aseptic conditions. The ampoules/vlals are sealed aseptically under nitrogen. The formulation contains 75.0±3.75 mg/2ml diclofenac sodium, as determined by validated HPLC. EXAMPLE 5 To produce 250 75mg/2ml diclofenac sodium units for IM or IV injection, 500ml water for injection (WFI) is purged with nitrogen gas to reduce the oxygen content to less than 0.5 mg/. The water was heated to 500C. Processing continues under a nitrogen gas blanket. 166.675g of HPBCD (DS 4.69) Is added to 60% of the WFI batch volume and is mixed until dissolved. The solution is then allowed to cool to room temperature. The solution Is pre-filtered with a 0.45pg filter, followed by the addition of 0.5 g NAC and 0.25 g EDTA. The solution Is stirred until all the NAC and EDTA Is dissolved. The pH Is then adjusted to 4.5. 18.75 g diclofenac sodium is added to the solution and stirred until dissolved and made up to 100% volume with WFI and the pH is adjusted to 7.4, should it be required. The resultant 75mg/2ml dlclofenac sodium solution Is sterilized by filtration with 0.22pm filters and filled Into pre-sterilized ampoules/vials under aseptic conditions. The ampoules/vials are sealed aseptically under nitrogen. The formulation contains 75.0±3.75 mg/2ml diclofenac sodium, as determined by validated HPLC. EXAMPLE 6 A production trial batch was produced according to the method as described in Example 5, whereby 15000 units of 75mg/2ml diclofenac sodium IM or IV units were produced. The stability of the formulations was monitored for 12 months at 25*C and 6 months at 40*C. The stability trial results are summarized in Table 6 below: WO 2005/092387 PCT/IB2004/003918 -12 Table 6 SCREENING STABILITY TRIAL DATA Diclofenac Sodium 75mg/2ml (control) Diclofenac Sodium 75mg/2ml Stoichiometry - 1:2 (NAC/EDTA) Control Batch (no stabilisers) Stoichiometry - 1:2 Amber ampoule Control Batch (0.05% EDTA + 0.1% NAC) Amber ampoule CONTROL BATCH STABILISED BATCH T=3 months 25 0 C 40 0 C 25 0 C 40 0 C Appearance Clear Clear Appearance Clear Clear, colourless yellow colourless slightly solution solution solution straw colourled solution pH 7.25 7.74 pH 7.14 7.56 Particulate Present Present Particulate Free from Free from Matter (under Matter visible visible direct light particulate particulate beam) matter matter Assay 73.95 73.57 Assay 72.96 72.90 mg/2ml mg/2ml mg/2ml mg/2ml (99.8% of (99.3% of (99.9% of (99.8% of T=0) T=0) T=0) T=0) Indolinone <0.1% 0.23% Indolinone nd 0.31% m/m / rrm Other nd Other nd nd T=6 months 25*C 40 0 C 25 0 C 40 0 C Appearance Straw Hazy, Appearance Clear Clear, coloured yellow - colourless slightly solution orange solution straw solution colourled solution pH 7.43 8.13 pH 7.25 8.47 Particulate Present Present Particulate Free from Free from Matter Matter visible visible particulate particulate matter matter Assay 74.81 74.28 Assay 73.47 72.88 mg/2ml mg/2ml mg/2ml mg/2ml (100.9%) (100.2%) (100.6%) (99.8%) Indollnone <0.1% 0.42% Indolinone <0.1% 0.62% m/m m/m Other nd 0.11% Other nd nd Smi/m T=9 months 25*C 40 0 C 25 0 C 40 0 C Appearance Straw N/A Appearance Clear N/A coloured coorless solution solution WO 2005/092387 PCT/IB2004/003918 -13 pH 7.53 N/A pH 7.36 N/A Particulate Present N/A Particulate Free from N/A Matter Matter visible particulate matter Assay 74.18 N/A Assay 73.32 N/A mg/2ml . mg/2ml (100.1%) (100.4%) Indolinone ' <0.1% N/A lndolinone 0.1% N/A Other nd N/A Other nd N/A T=12 months 25 0 C 40 0 C 25 0 C 40 0 C Appearance Straw NIA Appearance Clear N/A coloured colourless solution solution PH 7.62 N/A pH 7.28 N/A Particulate Present N/A Particulate Free from N/A Matter Matter visible particulate matter Assay 75.01 N/A Assay 74.59 N/A mg/2ml mg/2ml (101.2%) (102.1%) Indolinone <0.1% m/m N/A Indollnone 0.1% m/m N/A Other nd N/A Other nd N/A No physical or chemical Instability was observed for the trial batches after 12 months at 25 0 C and 6 months at 40*C. There was no apparent difference between the upright or vertical orientation of the formulations.

- 13a Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification (including the claims) they are to be interpreted as specifying the presence of the stated features, integers, steps or components, but not precluding the presence of one or more other features, integers, steps or components, or group thereof. 5 A reference herein to a patent document or other matter which is given as prior art is not to be taken as an admission that that document or matter was known or that the information it contains was part of the common general knowledge as at the priority date of any of the claims. 10

Claims (13)

1. A stable parenteral aqueous solution comprising either (a) diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or (b) an inclusion complex of dlclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or a mixture of (a) and (b), the solution containing; * diclofenac or diclofenac salt; * cyclodextrin; and * an antioxidant selected from monothioglycerol, or a combination of ethylene diamlne tetra-acetic acid and N-acetyl-cysteine.

2. The stable parenteral aqueous solution according to claim 1, wherein the diclofenac salt is diclofenac sodium.

3. The stable parenteral aqueous solution according to claim I or 2, wherein the cyclodextrin is 2-hydroxypropylbeta-cyclodextrin.

4. The stable parenteral aqueous solution according to claim 3, wherein the molar ratio of diclofenac to 2-hydroxypropyl beta cyclodextrin is 1:1.5 to 1:2.5.

5. The stable parenteral aqueous solution according to claim 4, wherein the molar ratio of diclofenac to 2-hydroxypropyl beta cyclodextrin is 1:2.

6. The stable parenteral aqueous solution according to any one of the preceding claims, comprising more than 25mg diclofenac or diclofenac salt per millilitre solution.

7. The stable parenteral aqueous solution according to claim 6, comprising 37.5mg diclofenac or diclofenac salt per millilitre solution. WO 2005/092387 PCT/IB2004/003918 -15

8. The stable parenteral aqueous solution according to any one of the preceding claims, wherein the antioxidant Is monothloglycerol and the monothloglycerol comprises 0.1 to 10mg per millilitre solution.

9. The stable parenteral aqueous solution according to claim 8, wherein the monothioglycerol comprises 0.1 to 5mg per millilitre solution.

10. The stable parenteral aqueous solution according to claim 9, wherein the monothioglycerol comprises 5mg per millilitre solution.

11. The stable parenteral aqueous solution according to any one of claims 1 to 7, wherein the antioxidant is a combination of ethylene diamine tetra-acetic acid and N-acetyl-cysteine, and the ethylene diamine tetra-acetic acid comprises 0.05 to 1 mg per millilitre solution and the N-acetyl-cystelne comprises 0.1 to 2 mg per millilitre solution.

12. The stable parenteral aqueous solution according to claim 11, wherein the ethylene diamine tetra-acetic acid comprises 0.5mg per millilitre solution and the N-acetyl-cysteine comprises 1mg per milllitre solution.

13. The stable parenteral aqueous solution according to any one of the preceding claims in the form of a unit dose that does not exceed 2 millilitres.